Coronavirus drugs: Using plasma from recovered patients as a treatment for COVID-19.
Int J Risk Saf Med
; 31(2): 47-51, 2020.
Article
in English
| MEDLINE | ID: covidwho-98445
Semantic information from SemMedBD (by NLM)
1. Patients LOCATION_OF Plasma
2. COVID-19 PROCESS_OF human group
3. Cessation of life PROCESS_OF Persons
4. Broadly Neutralizing Antibodies INTERACTS_WITH Specific antigen
5. Specific antigen PART_OF 2019 novel coronavirus
6. Patients LOCATION_OF Plasma
7. COVID-19 PROCESS_OF human group
8. Cessation of life PROCESS_OF Persons
9. Broadly Neutralizing Antibodies INTERACTS_WITH Specific antigen
10. Specific antigen PART_OF 2019 novel coronavirus
ABSTRACT
The ongoing COVID-19 pandemic has infected nearly 3,582,233 individuals with 248,558 deaths since it was first identified in human populations in December 2019 in Wuhan, China. No antiviral therapies or vaccines are available for their treatment or prevention. Passive immunization PI through broadly neutralizing antibodies that bind to the specific antigens of SARS-CoV 2 might be a potential solution to address the immediate health threat of COVID-19 pandemic while vaccines are being developed. The PI approach in treating COVID-19 is discussed herein, including a summary of its historical applications to confront epidemics.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Coronavirus Infections
/
Antibodies, Viral
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Int J Risk Saf Med
Year:
2020
Document Type:
Article
Affiliation country:
Jordan
Similar
MEDLINE
...
LILACS
LIS